acute coronary syndrome
Conditions
Interventions
1:Tegrilol 90 mg, b.i.d.
2:Tegrilol 60 mg, b.i.d.
Sponsors
Fuwai Central China Cardiovascular Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The effects of low-dose tegrilol (60mg,bid) and standard dose tegrilol (90mg,bid) on platelet aggregation must meet the following conditions: 1. Aged 18 to 85 years, regardless of gender; 2. Meet the diagnostic criteria of ACS; 3. Standard dose tigrilol (90mg, b.i.d.) in addition to aspirin; 4. Drug therapy was chosen instead of PCI after coronary angiography; 5. Voluntarily sign the informed consent.
Exclusion criteria
Exclusion criteria: It meets one of the following conditions 1. Allergic to aspirin and tegrillo; 2. Uncontrolled hypertension (> 180/110mmhg); 3. Stemiwithin 48 hours; 4. Had active bleeding within 3 months prior to enrollment, and was known to have one of coagulation diseases or platelet diseases; 5. Major surgery such as coronary artery bypass grafting (CABG) was performed within 1 month before inclusion and within the past 2 weeks; Severe physical trauma, CPR, angioplasty within 6 months; 6. The researchers believe it could affect the disease or cannot very good coordination with the research or likely to cause dangerous patients obviously, like alcoholism or drug abuse, cancer, severe liver, kidney, lung, and endocrine (uncontrolled diabetes or thyroid disease, for example), nerve or blood system diseases; 7. Known or suspected pregnancy (baseline ss-hcg pregnancy test must be performed for women in reproductive stage) Combined application of strong inducer or inhibitor of CYP P450 3A4, such as remifon, etc.. 9. Suspicious aortic dissection; 10. Anticoagulant drugs were used together during the study; 11. Coronary artery variant angina is completely normal; 12. There are serious laboratory abnormalities in the clinic, including: Abnormal platelet count ( 600*10^9/L) ALT > three times the normal upper limit, Blood creatinine > 220 µmol/L, Activated partial prothrombin time >1.3 times normal upper limit or INR > 1.5.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet aggregation rate; | — |
Countries
China
Contacts
Public ContactChuanyu Gao
Fuwai Central China Cardiovascular Hospital
Outcome results
None listed